Clinical Trials /

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

NCT04021043

Description:

This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving BMS-986156, ipilimumab, and nivolumab with or without stereotactic body radiation therapy will work better in treating patients with lung/chest or liver cancers.

Related Conditions:
  • Malignant Solid Tumor
Recruiting Status:

Recruiting

Phase:

Phase 1/Phase 2

Trial Eligibility

Document

Title

  • Brief Title: BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
  • Official Title: Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies

Clinical Trial IDs

  • ORG STUDY ID: 2018-0419
  • SECONDARY ID: NCI-2019-00405
  • SECONDARY ID: 2018-0419
  • SECONDARY ID: P30CA016672
  • NCT ID: NCT04021043

Conditions

  • Advanced Malignant Solid Neoplasm
  • Metastatic Carcinoma in the Liver
  • Metastatic Carcinoma in the Lung
  • Metastatic Malignant Neoplasm in the Thoracic Cavity
  • Metastatic Malignant Solid Neoplasm

Interventions

DrugSynonymsArms
Anti-GITR Agonistic Monoclonal Antibody BMS-986156Anti-GITR MoAb BMS-986156, BMS 986156, BMS-986156, GITR Agonist BMS-986156, TNFRSF18 Agonist BMS-986156Group I (ipilimumab, BMS-986156, nivolumab)
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, YervoyGroup I (ipilimumab, BMS-986156, nivolumab)
NivolumabBMS-936558, MDX-1106, NIVO, ONO-4538, OpdivoGroup I (ipilimumab, BMS-986156, nivolumab)

Purpose

This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung/chest or liver cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving BMS-986156, ipilimumab, and nivolumab with or without stereotactic body radiation therapy will work better in treating patients with lung/chest or liver cancers.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the safe dose of BMS-986156 and dose limiting toxicities (DLT) (30 mg versus
      [vs] 100 mg) when combined with ipilimumab (3 mg/kg) for patients with metastatic cancer.

      II. To evaluate the safety and toxicity profile of ipilimumab (3mg/kg) with BMS-986156 (30 or
      100 mg) administered in combination with stereotactic body radiation therapy (SBRT) targeting
      1-4 LIVER lesion(s) for patients with metastatic cancers.

      III. To evaluate the safety and toxicity profile of ipilimumab (3mg/kg) with BMS-986156 (30
      or 100 mg) administered in combination with SBRT targeting 1-4 LUNG lesion(s) for patients
      with metastatic cancer.

      IV. To determine safety and toxicity profile of nivolumab (480 mg) with BMS-986156 (30 mg)
      administered in combination with SBRT targeting 1-4 LIVER lesion(s) for patients with
      metastatic cancers.

      V. To determine safety and toxicity profile of nivolumab (480 mg) with BMS-986156 (30 mg)
      administered in combination with SBRT targeting 1-4 LUNG lesion(s) for patients with
      metastatic cancers.

      SECONDARY OBJECTIVES:

      I. To determine antitumor activity of ipilimumab therapy with BMS-986156 (30 or 100 mg) as
      well as nivolumab with BMS-986156 (30 mg) with SBRT treatment for 1-4 lung lesions in both
      the SBRT treated lesion and non-irradiate tumors.

      II. To determine antitumor activity of ipilimumab therapy with or without BMS-986156 (30 or
      100 mg) as well as nivolumab with BMS-986156 (30 mg) with SBRT treatment for 1-4 liver
      lesions in both the SBRT treated lesion and non-irradiate tumors.

      III. To compare response and progression of the non-irradiated tumors between BMS-986156 with
      ipilimumab vs BMS-986156 with nivolumab, using both immune-related response criteria (irRC)
      and Response Evaluation Criteria in Solid Tumors (RECIST) version (V) 1.1.

      IV. To evaluate the predictive potential value of tumor-associated and systemic immune
      biomarkers for therapy effectiveness and toxicity prediction.

      V. To evaluate whether skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor
      bulk are correlated with clinical outcomes and adverse events.

      VI. To evaluate whether tumor kinetics in combination with clinical correlates can help
      determine treatment response.

      VII. To evaluate whether tumor mutational burden correlates with improved clinical outcomes
      and response criteria.

      OUTLINE: This is a phase I, dose-escalation study of anti-GITR agonistic monoclonal antibody
      BMS-986156, followed by a phase II study. Patients are assigned to 1 of 3 groups.

      GROUP I: Patients receive ipilimumab intravenously (IV) over 90 minutes and anti-GITR
      agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every
      21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
      Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment
      repeats every 28 days for up to 26 cycles in the absence of disease progression or
      unacceptable toxicity.

      GROUP II: Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal
      antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4
      cycles in the absence of disease progression or unacceptable toxicity. After completion of
      cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10
      fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes.
      Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or
      unacceptable toxicity.

      GROUP III: Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal
      antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes
      on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days
      for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal
      antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days, then every 2-4
      months for up to 1 year.
    

Trial Arms

NameTypeDescriptionInterventions
Group I (ipilimumab, BMS-986156, nivolumab)ExperimentalPatients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
  • Anti-GITR Agonistic Monoclonal Antibody BMS-986156
  • Ipilimumab
  • Nivolumab
Group II (ipilimumab, BMS-986156, SBRT, nivolumab)ExperimentalPatients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
  • Anti-GITR Agonistic Monoclonal Antibody BMS-986156
  • Ipilimumab
  • Nivolumab
Group III (nivolumab, BMS-986156, SBRT)ExperimentalPatients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
  • Anti-GITR Agonistic Monoclonal Antibody BMS-986156
  • Nivolumab

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have histological confirmation of solid metastatic cancer with at least
             one metastatic or primary lesion in the liver or lung/chest, except for group 1.

          -  Patients who have completed prior systemic anti-cancer therapies, an interval of 5
             drug half-lives or 4-weeks whichever is shorter, is required, prior to enrollment on
             study. Note: patients with anaplastic thyroid will be waived from this inclusion
             criteria given the rapid trajectory of their disease

          -  All patients must have at least one metastatic or primary lesion within the lung/chest
             or liver located in an anatomical location amenable to SBRT treatment with 50 Gy in 4
             fractions or with 60 Gy in 10 fractions, except for group 1.

          -  Repeat radiation in fields previously radiated will be allowed at the discretion of
             the treating physician

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky > 60%)

          -  Total bilirubin =< 2.0 mg/dL (does NOT apply to patients with Gilbert's syndrome) (use
             of growth factors or blood transfusion to achieve these requirements is not allowed 2
             weeks prior to study enrollment)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             < 2.5 x institutional upper limit of normal (use of growth factors or blood
             transfusion to achieve these requirements is not allowed 2 weeks prior to study
             enrollment)

          -  White blood count (WBC) >= 2500/uL (use of growth factors or blood transfusion to
             achieve these requirements is not allowed 2 weeks prior to study enrollment)

          -  Absolute neutrophil count (ANC) >= 1000/uL (use of growth factors or blood transfusion
             to achieve these requirements is not allowed 2 weeks prior to study enrollment)

          -  Platelets >= 75K (use of growth factors or blood transfusion to achieve these
             requirements is not allowed 2 weeks prior to study enrollment)

          -  Hemoglobin >= 9 g/dL (use of growth factors or blood transfusion to achieve these
             requirements is not allowed 2 weeks prior to study enrollment)

          -  Creatinine =< 2.0 x upper limit of normal (ULN) (use of growth factors or blood
             transfusion to achieve these requirements is not allowed 2 weeks prior to study
             enrollment)

          -  Patients must be willing and able to review, understand, and provide written consent
             before starting therapy

          -  Patients with brain metastasis will be included as long as they are free of neurologic
             symptoms related to metastatic brain lesions and who do not require or receive
             systemic corticosteroid therapy, > 10 mg/day in the 14 days prior to beginning the
             trial (=< 10 mg steroid, e.g.: prednisone, is allowed). Patients with stable brain
             metastases (clinically and radiographically) for >= 4 weeks to enroll on the protocol.

          -  Patients that have previously progressed on immunotherapy such as ipilimumab,
             anti-PD-I, anti-PDL-1 or talimogene laherparepvec (T-VEC) will be eligible.

        Exclusion Criteria:

          -  Serious autoimmune disease at the discretion of the treating attending: patients with
             a history of active serious inflammatory bowel disease (including Crohn's disease and
             ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic
             progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune
             vasculitis (e.g., Wegener's granulomatosis) are excluded from this study

          -  Active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction,
             abdominal carcinomatosis or other known risk factors for bowel perforation

          -  Any underlying medical or psychiatric condition, which in the opinion of the
             Investigator, will make the administration of study drug hazardous or obscure the
             interpretation of adverse events (AEs): e.g. a condition associated with frequent
             diarrhea or chronic skin conditions, recent surgery or colonic biopsy from which the
             patient has not recovered, or partial endocrine organ deficiencies

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, history of congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has
             not been documented to be stable

          -  Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to
             one month prior to or after any dose of ipilimumab)

          -  Concomitant therapy with any of the following: IL-2, interferon or other non-study
             immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other
             investigational therapies; or chronic use of systemic corticosteroids while receiving
             ipilimumab (as long as steroid replacement is significantly greater than what is
             required for physiologic replacement, i.e. in hypothyroidism)

          -  Pregnant women are excluded from this study. Women of child-bearing potential (WOCBP)
             must have a pregnancy test every 4 weeks and WOCBP must have a negative serum or urine
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic
             gonadotropin [HCG]) within 24 hours prior to the start of immunotherapy drugs
             (ipilimumab/nivolumab/BMS-986156), during the course of the treatment and 160 days
             AFTER the last dose of study drug you should not get pregnant or breast feed. In the
             case of male participants, during the course of treatment and 220 days AFTER the last
             dose of immunotherapy you should not father a child (condom use is mandatory, even if
             vasectomized) or donate sperm. For contraception guidelines please see protocol

          -  History of or current immunodeficiency disease or prior treatment compromising immune
             function at the discretion of the treating physician

          -  Prior allogeneic stem cell transplantation

          -  Patients who were intolerant to previous immuno-oncology (IO) drugs should be excluded
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Incidence of dose-limiting toxicities (DLT)
Time Frame:Up to 29 days for groups 1 and 3, up to day 43 for group 2
Safety Issue:
Description:Descriptive statistics will be computed.

Secondary Outcome Measures

Measure:Treatment Success Defined by Immune-related Responses
Time Frame:Up to 1 year
Safety Issue:
Description:Assessment of antitumor activity of ipilimumab & nivolumab with BMS-986156 & SBRT for 1-4 lung lesions in both SBRT treated lesion and non-irradiate tumors where treatment success defined as immune-related complete response (irCR) or immune-related partial response (irPR) or immune-related stable disease (irSD), assessed using immune-related response criteria (irRC) (e.g. the best response obtained by a patient).irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden ≥50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation.
Measure:Treatment Success Defined by Immune-related Responses
Time Frame:Up to 1 year
Safety Issue:
Description:Assessment of antitumor activity of ipilimumab with or without BMS-986156 as well as nivolumab with BMS-986156 with SBRT treatment for 1-4 liver lesions in both the SBRT treated lesion and non irradiate tumors where treatment success defined as irCR or irPR or irSD, assessed using irRC (e.g. the best response obtained by a patient).irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden ≥50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation. Clinical benefit established as having irSD for up to 6 months for irSD.
Measure:Response of non-irradiated tumors
Time Frame:Up to 1 year
Safety Issue:
Description:Comparison of response of non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab done using irRc (e.g. the best response obtained by a patient).irRc efined as irCR, complete disappearance all lesions (whether measurable or not, no new lesions) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; irPR, decrease in tumor burden ≥50% relative to baseline confirmed by consecutive assessment at least 4 week after first documentation; irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded tumor burden) confirmation by repeat, consecutive assessment no less than 4 weeks from date first documented; ; irSD, not irCR or irPR, in absence of irPD, does not require repeat confirmation. Clinical benefit established as having irSD for up to 6 months for irSD.Comparisons between groups will be assessed with regard to the irRC outcomes.
Measure:Predictive potential value of tumor-associated and systemic immune biomarkers
Time Frame:Up to 1 year
Safety Issue:
Description:For the predictive potential value of tumor-associated and systemic immune biomarkers, comparisons will be performed between group 2 (Ipilimumab plus BMS-986156 with SBRT) and group 3 (Nivolumab plus BMS-986156 with SBRT) per treatment site (liver or lung). Potential values may be summarized as qualitative or descriptive lists.
Measure:Adverse events will be evaluated using skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk.
Time Frame:Up to 1 year
Safety Issue:
Description:It will be evaluated whether skeletal mass, neutrophil, neutrophil to lymphocyte ratio, and tumor bulk are correlated with clinical outcomes and adverse events.Correlation may be summarized as qualitative or descriptive list of item's possible association to clinical outcome and/or adverse event.
Measure:Treatment response
Time Frame:Up to 1 year
Safety Issue:
Description:It will be evaluated whether tumor kinetics in combination with clinical correlates can help determine treatment response. The radiological response and clinical data will be analyzed using mathematical and statistical models to identify prognostic groups.
Measure:Tumor mutational burden
Time Frame:Up to 1 year
Safety Issue:
Description:Will be correlated with improved clinical outcomes and response criteria.
Measure:Progression of non-irradiated tumors
Time Frame:Up to 1 year
Safety Issue:
Description:Comparison of progression of non-irradiated tumors between BMS-986156 with ipilimumab vs BMS-986156 with nivolumab done using irRc where treatment success defined as Response Evaluation Criteria in solid Tumors (RECIST) version 1.1: Complete Response (CR): Disappearance all target lesions; Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): At least 20% increase in sum LD target lesions, reference smallest sum LD recorded since treatment started or appearance 1/> new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD since treatment started

Details

Phase:Phase 1/Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:M.D. Anderson Cancer Center

Last Updated